Clinical Trial

Investigation of Growth Hormone and Platelet-Rich Plasma on Joint Health

Not Yet Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This clinical study will evaluate the efficacy of intra-articular (IA) injection of growth hormone (HGH) and platelet-rich plasma (PRP) in adults with knee and ankle arthritis resistant to conventional treatment. The study, sponsored by Integrant Pty Ltd and led by Prof. Gordon Slater, aims to determine whether IA HGH injections can enhance cartilage regeneration and joint healing. The study will recruit 60 patients who will receive three IA injections of HGH and PRP spaced 7-16 days of each other. Outcomes will be assessed using AOFAS and AKS scoring systems at 3- and 6-months post-treatment. The study hypothesizes that HGH will increase healing of arthritic or injured joints compared to standard treatment, potentially providing a non-surgical alternative for patients with treatment-resistant arthritis.
Trial Details
NCT Number NCT06907121
Lead Sponsor Integrant Pty Ltd
Collaborators: University of Technology, Sydney
Conditions Arthritis Ankle, Arthritis Knee
Enrollment 60 participants
Start Date 2025-06-01
Primary Completion 2027-12-01 (estimated)
Study Completion 2027-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-04-02